ArticleScience translational medicine2022
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 52 citations in OpenAlex.
- Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis.Materials today. Bio · 2026Article
- Sex-Biased Immunity: The Hidden Variable in Immuno-oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Inhibition of the programmed death protein 1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischaemia.Cardiovascular research · 2026Article
- Trends in cardiovascular mortality among lung cancer patients in the United States: a retrospective study from 1999 to 2023.Cardio-oncology (London, England) · 2026Article
- Review
- Sex matters: mechanistic insights into sex-driven patterns of autoimmunity and implications for pharmacotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.Journal of the American Heart Association · 2026Article
- Immune checkpoint inhibition and heart injury: molecular mechanisms and clinical challenges.ESC heart failure · 2026Review
- Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity.Frontiers in cardiovascular medicine · 2026Review
- Cardiotoxicity associated with anticancer therapies for gynecological tumors.Frontiers in cardiovascular medicine · 2026Review
- Immunotherapy-associated Cardiotoxicity: a Comprehensive Review of Checkpoint inhibitors, monoclonal, cellular, and cytokine-based Treatments.Current treatment options in oncology · 2025Review
- From tumor immunotherapy to myocardial injury: A mechanistic discussion of immune checkpoint inhibitor‑related myocarditis (Review).Molecular medicine reports · 2025Review
- MLKL-Mediated Necroptosis Predominantly Contributes to Immune-Associated Myocardial Damage.Inflammation · 2025Article
- Resident Macrophage-Orchestrated Immune and Fibroblast Interactions in Immune Checkpoint Inhibitor-Associated Nephrotoxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study.European journal of medical research · 2025Article
- Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Investigation of MANF regulation of glioma stemness via STAT3/TGF-β/SMAD4/p38 pathway based on pan-cancer analysis.Translational oncology · 2025Article
- Modelling the ageing dependence of cancer evolutionary trajectories.Nature reviews. Cancer · 2025Review
- N6-methyladenosine-mediated upregulation of MANF promotes ER stress resistance in renal cell carcinoma.Cell death & disease · 2025Article
- Unmasking the Rare but Lethal Cardiac Complications of Immune Checkpoint Inhibitor Therapy: A Review of Mechanisms, Risk Factors, and Management Strategies.Current treatment options in oncology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
31 authors at 10 institutions in 5 countries.
Yaohua ZhangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9741-591X
Chengcao SunDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0554-3165
Yajuan LiDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2328-6956
Juan QinSection of Cardio-Oncology and Immunology, Division of Cardiology and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-0821-6290
Kaushik AmancherlaDepartment of Medicine, Vanderbilt University of Medical Center, Nashville, TN 37232, USA.
Ying JingDepartment of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX 77030, USA.
Qingsong HuDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ke LiangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zhao ZhangDepartment of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX 77030, USA.ORCID 0000-0002-3757-8469
Youqiong YeDepartment of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX 77030, USA.ORCID 0000-0001-8332-4710
Lisa A HuangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tina K NguyenDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sergey D EgranovDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6806-281X
Zilong ZhaoDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6607-4596
Andrew WuDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7579-6363
Yutao XiTexas Heart Institute, St. Luke's Hospital, Houston, TX 77030, USA.
Jun YaoDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-1418-3576
Mien-Chie HungGraduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.ORCID 0000-0003-4317-4740
George A CalinDivision of Cancer Medicine, Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jie ChengTexas Heart Institute, St. Luke's Hospital, Houston, TX 77030, USA.
Bora LimDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4182-6058
Lorenz H LehmannDepartment of Cardiology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-5077-8580
Joe-Elie SalemDepartment of Pharmacology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, INSERM, CIC-1901, UNICO-GRECO Cardiooncology Program, Paris, France.ORCID 0000-0002-0331-3307
Douglas B JohnsonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Michael A CurranDepartment of Immunology and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT), University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4996-7207
Dihua YuDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6231-9381
Leng HanCenter for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.ORCID 0000-0002-7380-2640
Radbod DarabiCenter for Stem Cell and Regenerative Medicine (CSCRM), Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Liuqing YangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6518-474X
Javid J MoslehiSection of Cardio-Oncology and Immunology, Division of Cardiology and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-5443-4312
Chunru LinDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6473-8229
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · USSt. Luke's Episcopal Hospital · USUniversity of California, San Francisco · USVanderbilt University Medical Center · USAsia University · TWBrown Foundation · USGerman Cancer Research Center · DEInserm · FRPrevention Institute · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MImmunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3MLong-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3MLong Noncoding RNA Advocates Immune Resistant MicroenvironmentR01CA231011 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2019 to 2023
$2.9M(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibitionR01CA227481 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BALKO, JUSTIN M, JOHNSON, DOUGLAS B · 2019 to 2023
$2.6MSignificance of Inhibiting Long Non-coding RNAs in Advanced Breast CancerR01CA218025 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2017 to 2020
$1.5MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA218025NCI NIH HHS R01 CA227481NCI NIH HHS R01 CA231011NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021
Abstract
Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer treatment but are associated with myocarditis. Here, we report that tumor-bearing mice exhibited response to treatment with combinatorial anti-programmed cell death 1 and anti-cytotoxic T lymphocyte antigen-4 antibodies but also presented with cardiovascular toxicities observed clinically with ICI therapy, including myocarditis and arrhythmia. Female mice were preferentially affected with myocarditis compared to male mice, consistent with a previously described genetic model of ICI myocarditis and emerging clinical data. Mechanistically, myocardial tissue from ICI-treated mice, the genetic mouse model, and human heart tissue from affected patients with ICI myocarditis all exhibited down-regulation of
Indexed as
MyocarditisAnimalsEstradiolEstrogen Receptor betaFemaleHumansImmune Checkpoint InhibitorsMaleMiceMyocytes, CardiacNerve Growth FactorsEstradiolEstrogen Receptor betaImmune Checkpoint InhibitorsMANF protein, humanMANF protein, mouseNerve Growth Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.